OPKO HEALTH, INC.

OPK
About the company

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.

Country: United StatesPrice: $1.68Market Cap: $1.2B

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

10 of 12 pass — Buffett and Marks object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictPASSFAILFAILFAIL · Rank #2360 (Top 76.2%)PASSFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage83% pass✓ 13✗ 2▾

    10 of 12 pass — Buffett and Marks object

    LT Debt vs Net Current AssetsLT Debt $1.6M vs NCA $643.9M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: -2.7x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt$382.5M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change0.14% -> 0.12%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities4.97
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-2.7x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0025; #432/4210 (top 10.3%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 5✗ 23▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / Book Value per Share1.0x
    ✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.0x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-14.7%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-14.7%, ROC=-38.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Valuation ReasonablenessOE Yield=-11.5%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-15.3%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=1.0x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low149% of trailing low ($1.13)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-11.87%; #4258/6340 (top 67.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.8948; #1688/6449 (top 26.2%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share4.77x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-33.0%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.4021; #2921/5247 (top 55.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-10.85%; #3269/4519 (top 72.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+44.83%; #732/6202 (top 11.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-146.3M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-190.8M
    ✗LynchPositive and growing
    Operating Cash Flow$-178.5M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-9.24%, ROA=-11.68%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-15.3%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive4/17 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-10.6%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency4/17 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-135.3M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-10.85%; #3269/4519 (top 72.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 1✗ 12▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -22.1% vs Rev: -21.9%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-14.9%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 36.8% -> 33.9%, operating margin -18.2% -> -19.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-15.8%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 4✗ 31▾

    15 of 16 flag OPK's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)2/25 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/25 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-11.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-19.3% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-146.3M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-13.3%
    ✗Lynch> 15%
    EBIT / Enterprise Value-14.7%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-14.7%, ROC=-38.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-11.68%
    ✗PiotroskiROA > 0
    ROA Change YoY-2.42% -> -11.68% (delta: -9.26%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-9.24%, ROA=-11.68%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY30.6% -> 33.9%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-32.7%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-13.3%
    ✗Dreman> 12%
    Margin of SafetyP/B=1.0x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-11.8% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-25.5%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-13.3%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-18.2% (2023) -> -19.3% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 36.8% -> 33.9%, operating margin -18.2% -> -19.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-11.87%; #4258/6340 (top 67.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+12.33%; #2624/3702 (top 70.9%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-13.26%; #3520/5226 (top 67.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0535; #2658/5884 (top 45.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts13% pass✓ 2✗ 14▾

    Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

    Overall verdict
    ✓GrahamPASS (4/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #2360✓PiotroskiPASS (F-Score 4)✗DremanFAIL (4/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1059/2370 (Top 44.7%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag OPK's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio4.97
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-7.5%
    ✗Buffett> 10%
    ROIC - WACC-17.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-38.8%
    ✗Greenblatt> 25%
    Current Ratio Change YoY3.43 -> 3.97
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.32x -> 0.31x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities4.97
    ✓Dreman> 1.5
    Return on Invested Capital-9.0%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-8.9%; FY2024: ROIC=-6.7%; FY2025: ROIC=-5.7%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -5.7%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Small Cap($1.2B)
Revenue: $606.9M-14.9% YoY
Net Income: $225.7M-324.0% YoY

Financial Snapshot

Operating Margin-19.3%
Return on Equity-17.8%
Debt / Equity0.27
Current Ratio3.97
EPS (Diluted)$-0.30
Buybacks (1y)$47.0M
Buybacks (2y)$137.3M
Shares Retired−13.0% / 1.8% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 13.0% of shares last year, 1.8% over two.

Buybacks
$47.0M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-26
FY 2024
Sources
  • 10-K · 2025-03-03
FY 2023
Sources
  • 10-K · 2025-03-03
FY 2022
Sources
  • 10-K · 2023-02-27
FY 2021
Sources
  • 10-K · 2022-03-01
Market Cap$1.2Bcurrent------$956.4Mest.$1.0Best.$788.7Mest.$996.7Mest.$2.1Best.
Revenue$501.6M↓22%$65.4M↓57%$163.6M↑4%$124.2M↓17%$606.9M↓15%$713.1M↓17%$863.5M↓14%$1.0B↓43%$1.8B
Operating Income-$127.7M↓14%-$31.4M↓165%-$7.0M↑88%-$51.0M↑24%-$117.4M↑23%-$152.1M↑3%-$157.0M↑31%-$226.3M↓1307%$18.8M
Net Income-$148.1M↑18%-$53.5M↓347%-$8.4M↑94%-$54.8M↑19%-$225.7M↓324%-$53.2M↑72%-$188.9M↑42%-$328.4M↓989%-$30.1M
EPS (Diluted)--$-0.07↓333%$-0.01↑95%$-0.07$-0.30↓275%$-0.08↑68%$-0.25↑46%$-0.46↓820%$-0.05
Gross Margin46.2%64.3%↑95%48.9%↑55%36.8%↑30%33.9%↑11%30.6%↓17%36.8%↑28%28.7%—
Operating Margin-25.5%↓46%-48.0%↓252%-4.3%↑89%-41.1%↑8%-19.3%↑9%-21.3%↓17%-18.2%↑19%-22.5%↓2233%1.1%
ROE-13.3%↑4%———-17.8%↓357%-3.9%↑71%-13.6%↑35%-21.0%↓1076%-1.8%
Total Debt$2.8M↓31%$2.8M↓31%$2.7M↓37%$3.5M↓17%$346.2M↓21%$440.2M↑4429%$9.7M↓12%$11.0M↑277%$2.9M
Shareholders' Equity$1.1B↓15%$1.1B↓15%$1.2B↓9%$1.2B↓8%$1.3B↓7%$1.4B↓2%$1.4B↓11%$1.6B↓7%$1.7B
Current Ratio4.97↑34%4.97↑34%3.35↓2%3.61↑45%3.97↑16%3.43↑122%1.55↓16%1.85↓26%2.49
Debt / Equity0.00↓19%0.00↓19%0.00↓31%0.00↓10%0.27↓15%0.32↑4508%0.01↓1%0.01↑306%0.00
Operating Cash Flow-$125.0M-$36.3M↓5%-$43.5M↑48%-$19.3M↑44%-$178.5M↑3%-$183.5M↓551%-$28.2M↑70%-$95.2M↓348%$38.3M
Free Cash Flow-$135.3M-$39.1M↓3%-$46.5M↑46%-$21.1M↑44%-$190.8M↑8%-$208.5M↓369%-$44.5M↑63%-$119.8M↓2038%$6.2M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

OPK vs Peers — Financial Grading

Revenue$606.9MBottom 25%
Net Income$225.7MBottom 25%
ROE-17.8%Bottom 25%
D/E0.27Median
Op. Margin-19.3%Bottom 25%
Curr. Ratio3.97Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11